Unsere Publikationen

A role of the norepinephrine system or effort in the interplay of different facets of inhibitory control

Link
https://doi.org/10.1016/j.neuropsychologia.2022.108143
Tags
Autonomes Nervensystem & NeuroendokrinologieAndere
Jahr
2022
Autoren
Yu S, Ghin F, Mückschel M, Ziemssen T, Stock A, Beste C.
Verlag
Neuropsychologia 2022;166.
Zum Eintrag

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.

Link
https://doi.org/10.3389/fimmu.2022.852563
Tags
Multiple SkleroseMS BehandlungNeuroimmunologie
Jahr
2022
Autoren
Ziemssen T, Arnold DL, Alvarez E, Cross AH, Willi R, Li B, Kukkaro P, Kropshofer H, Ramanathan K, Merschhemke M, Kieseier B, Su W, Häring DA, Hauser SL, Kappos L, Kuhle J.
Verlag
Front Immunol. 2022 Mar 31;13:852563.
Zum Eintrag

CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

Link
https://doi.org/10.1177/13524585211032803
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M.
Verlag
Mult Scler. 2022 Apr;28(4):608-619.
Zum Eintrag

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Link
https://doi.org/10.1177/13524585211061335
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T.
Verlag
Mult Scler. 2022 Apr;28(5):842-846.
Zum Eintrag

Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany

Link
https://doi.org/10.2217/nmt-2021-0031
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Ziemssen T, Kurzeja A, Muresan B, Haas JS, Alexander J, Driessen MT.
Verlag
Neurodegenerative Dis Manage 2022;12(2):93-107.
Zum Eintrag

Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations

Link
https://doi.org/10.1002/mds.28946
Tags
NeuroimmunologieAndere
Jahr
2022
Autoren
Ziemssen T, Akgun K, Członkowska A, Antos A, Bembenek J, Kurkowska-Jastrzębska I, Przybyłkowski A, Skowrońska M, Smolinski L, Litwin T.
Verlag
Mov Disord. 2022 May;37(5):1074-1079.
Zum Eintrag

Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study

Link
https://doi.org/10.3389/fneur.2022.863105
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Weber MS, Buttmann M, Meuth SG, Dirks P, Muros-Le Rouzic E, Eggebrecht JC, Hieke-Schulz S, Leemhuis J, Ziemssen T.
Verlag
Front Neurol. 2022 May 9;13:863105.
Zum Eintrag

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

Link
https://doi.org/10.1007/s00415-021-10931-w
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Ziemssen T, Lang M, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Lang S, Winkelmann VE, Ettle B, Schulze-Topphoff U; PANGAEA study group.
Verlag
J Neurol. 2022 Jun;269(6):3276-3285.
Zum Eintrag

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-